1
|
Kremer C, Gdovinova Z, Bejot Y, Heldner MR, Zuurbier S, Walter S, Lal A, Epple C, Lorenzano S, Mono ML, Karapanayiotides T, Krishnan K, Jovanovic D, Dawson J, Caso V. European Stroke Organisation guidelines on stroke in women: Management of menopause, pregnancy and postpartum. Eur Stroke J 2022; 7:I-XIX. [PMID: 35647308 PMCID: PMC9134774 DOI: 10.1177/23969873221078696] [Citation(s) in RCA: 15] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2021] [Accepted: 01/19/2022] [Indexed: 01/01/2023] Open
Abstract
Pregnancy, postpartum and menopause are regarded as periods women are more
vulnerable to ischaemic events. There are conflicting results regarding stroke
risk and hormone replacement therapy (HRT) during menopause. Stroke in pregnancy
is generally increasing with serious consequences for mother and child;
therefore, recommendations for acute treatment with intravenous thrombolysis
(IVT) and/or mechanical thrombectomy (MT) are needed. The aim of this guideline
is to support and guide clinicians in treatment decisions in stroke in women.
Following the “Grading of Recommendations and Assessment, Development and
Evaluation (GRADE)” approach, the guidelines were developed according to the
European Stroke Organisation (ESO) Standard Operating Procedure. Systematic
reviews and metanalyses were performed. Based on available evidence,
recommendations were provided. Where there was a lack of evidence, an expert
consensus statement was given. Low quality of evidence was found to suggest
against the use of HRT to reduce the risk of stroke (ischaemic and haemorrhagic)
in postmenopausal women. No data was available on the outcome of women with
stroke when treated with HRT. No sufficient evidence was found to provide
recommendations for treatment with IVT or MT during pregnancy, postpartum and
menstruation. The majority of members suggested that pregnant women can be
treated with IVT after assessing the benefit/risk profile on an individual
basis, all members suggested treatment with IVT during postpartum and
menstruation. All members suggested treatment with MT during pregnancy. The
guidelines highlight the need to identify evidence for stroke prevention and
acute treatment in women in more vulnerable periods of their lifetime to
generate reliable data for future guidelines.
Collapse
Affiliation(s)
- Christine Kremer
- Neurology Department, Clinical Sciences Lund University, Skåne University Hospital, Malmö, Sweden
| | - Zuzana Gdovinova
- Neurology Department, Faculty of Medicine, Pavol Jozef Safarik University Košice, Košice, Slovakia
| | - Yannick Bejot
- Dijon Stroke Registry, Pathophysiology and Epidemiology of Cerebro-Cardiovascular diseases (PEC2), University of Burgundy, University Hospital of Dijon, Dijon, France
| | - Mirjam R Heldner
- Department of Neurology, Inselspital, University Hospital and University of Bern, Bern, Switzerland
| | - Susanna Zuurbier
- Department of Neurology, Amsterdam University Medical Centers, Amsterdam, Netherlands
| | - Silke Walter
- Department of Neurology, Saarland University, Homburg, Germany
| | - Avtar Lal
- European Stroke Organisation (ESO), Basel, Switzerland
| | - Corina Epple
- Department of Neurology, Klinikum Hanau, Hanau, Germany
| | - Svetlana Lorenzano
- Department of Human Neurosciences, Sapienza University of Rome, Rome, Italy
| | - Marie-Luise Mono
- Department of Neurology, Municipal Hospital Waid und Triemli, Zürich, University Hospital and University of Bern, Bern Switzerland
| | - Theodore Karapanayiotides
- 2nd Department of Neurology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece
| | - Kailash Krishnan
- Stroke, Department of Acute Medicine, Queens Medical Centre, Nottingham University Hospitals NHS Trust, Nottingham, UK
| | - Dejana Jovanovic
- Department of Emergency Neurology, Neurology Clinic, Medical Faculty, University Clinical Center of Serbia, University of Belgrade, Belgrade, Serbia
| | - Jesse Dawson
- Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow, United Kingdom
| | - Valeria Caso
- Stroke Unit, Santa Maria della Misericordia Hospital, University of Perugia Perugia, Italy
| |
Collapse
|
2
|
Kanaji N, Kume K, Mizoguchi H, Inoue T, Watanabe N, Nishiyama N, Kadowaki N, Ishii T. Subacute Sensorimotor Neuropathy Accompanied by Anti-ganglioside GM1 Antibody in a Patient with Lung Cancer. Intern Med 2018; 57:3289-3292. [PMID: 29984773 PMCID: PMC6288004 DOI: 10.2169/internalmedicine.0667-17] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
A 66-year-old man presented with subacute sensorimotor neuropathy in association with small cell lung cancer. Tests for the anti-ganglioside antibody GM1-IgM were positive. Chemotherapy and intravenous immunoglobulin treatment led to a slight improvement in neurological symptoms. Four additional cases of neuropathy accompanied by anti-ganglioside antibody and lung cancer have been reported. The most commonly reported pattern was subacute sensorimotor neuropathy. Patients died from cancer progression after 5 to 18 months. There is evidence that anti-ganglioside antibody inhibits tumor progression, prolonging the patient survival. However, severe neurological disturbance may offset the survival benefit of anti-ganglioside antibody in patients with paraneoplastic neurological syndrome.
Collapse
Affiliation(s)
- Nobuhiro Kanaji
- Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Japan
| | - Kodai Kume
- Department of Internal Medicine, Division of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Japan
| | - Hitoshi Mizoguchi
- Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Japan
| | - Takuya Inoue
- Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Japan
| | - Naoki Watanabe
- Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Japan
| | - Noriko Nishiyama
- Department of Internal Medicine, Division of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Japan
| | - Norimitsu Kadowaki
- Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Japan
| | - Tomoya Ishii
- Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Japan
| |
Collapse
|